| OPPOSITION | - Anonymous, "Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58 th Annual Meeting of the American Society of Hematology", businesswire, (20161204), XP093276475 | - |
| OPPOSITION | - Anonymous, "Acceleron Announces New Data Presentations at the 2015 American Society of Hematology Annual Meeting", businesswire, (20151105), XP093266238 | - |
| OPPOSITION | - Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN) - RECOMMENDED International Nonproprietary Names: List 72", WHO DRUG INFORMATION, GENEVA, CH, CH , (20140101), vol. 28, no. 3, ISSN 1010-9609, pages 379 - 422, XP093266221 | - |
| OPPOSITION | - Anonymous, "JAKAFI® (ruxolitinib) tablets, for oral use - HIGHLIGHTS OF PRESCRIBING INFORMATION", FDA, FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202192s009lbl.pdf, XP093266153 | - |
| OPPOSITION | - Anonymous, "Myelofibrosis Facts", Leukemia & Lymphoma Society (LLS) FS14, Leukemia & Lymphoma Society (LLS) FS14, URL: https://www.lls.org/sites/default/files/file_assets/FS14_Myelofibrosis%20Fact%20Sheet.pdf, XP093266246 | - |
| OPPOSITION | - Anonymous, "REBLOZYL ® (luspatercept-aamt) for injection, for subcutaneous use - HIGHLIGHTS OF PRESCRIBING INFORMATION", FDA, FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761136orig2lbl.pdf, XP093266226 | - |
| OPPOSITION | - Anonymous, "UCB 2013 Annual Report. Inspired by patients. Driven by science.", pages 1 - 156, URL: https://www.ucb.com/_up/ucb_com_ir/documents/2013_Annual_report_ENG.pdf, (20190313), XP055568393 | - |
| OPPOSITION | - Anonymous, "Vidaza FDA Approval History", Drugs.com, Drugs.com, URL: https://www.drugs.com/history/vidaza.html, XP093266200 | - |
| OPPOSITION | - Antonio G. Piga, Silverio Perrotta, Angela Melpignano, Caterina Borgna-Pignatti, Ersi Voskaridou, Vincenzo Caruso, Aldo Filosa, Yesim Aydinok, Carrie Condon, Dawn M. Wilson, Adberrahmane Laadem, Matthew L. Sherman, And Kenneth M. Attie, "ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20140101), vol. 124, no. 21, ISSN 0006-4971, page 53, XP055396217 | - |
| OPPOSITION | - Bronson Sarah, "New Drugs for myeloproliferative neoplasms ease suffering and extend life", The University of Texas; MD Anderson Cancer Center, The University of Texas; MD Anderson Cancer Center, URL: https://www.mdanderson.org/publications/cancer-frontline/myeloproliferative-neoplasm-drugs-ease-suffering-extend-life.h00-158914068.html, XP093276486 | - |
| OPPOSITION | - Celgene (responsible Party), "A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence - NCT03194542", Clinical Trials, ClinicalTrials.gov, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT03194542?tab=history&a=1#version- content-pane, XP093266231 | - |
| OPPOSITION | - D39 - Celgene Reports Fourth Quarter and Full-Year 2016 Operating and Financial Results, 26 January 2017 | - |
| OPPOSITION | - D42 - Platzbecker et al. 2014 presentation at ASH 2014 “Luspatercept (ACE-536) increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results form a Phase 2 Study” | - |
| OPPOSITION | - D43 - Platzbecker et al. 2015 presentation at EHA 2015 “Luspatercept increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from a phase 2 study” | - |
| OPPOSITION | - D44 - Platzbecker et al. 2016 presentation at EHA 2016 (June 9-12, 2016) “Luspatercept increases hemoglobin and reduces transfusion burden in patients with low-intermediate risk myelodysplastic syndromes (MDS): long-term results from phase 2 PACE-MDS study” | - |
| OPPOSITION | - D4 - United States Securities and Exchange Commission Form 10-K - Annual Report pursuant to section 13 or 15(d) of the securities exchange act of 1934, for the fiscal year ended December 31, 2016; Introduction and Part I is submitted; available online from the EDGAR database on 1 March 2017 | - |
| OPPOSITION | - D5 - Proof for public availability of D4 provided as screenshots. | - |
| OPPOSITION | - Fda, "FDA Jakafi Label", (20231031), XP093096965 | - |
| OPPOSITION | - Gale, R.P. ; Barosi, G. ; Barbui, T. ; Cervantes, F. ; Dohner, K. ; Dupriez, B. ; Gupta, V. ; Harrison, C. ; Hoffman, R. ; Kiladjian, J.J. ; Mesa, R. ; Mc Mullin, M.F. ; Passamonti, F. ; Ribrag, V. ; Roboz, G. ; Saglio, G. ; Vannucchi, A. ; Verstovsek, S., "What are RBC-transfusion-dependence and -independence?", Leukemia Research, NEW YORK,NY, US, US , (20110101), vol. 35, no. 1, ISSN 0145-2126, pages 8 - 11, XP027561457 | - |
| OPPOSITION | - Inman Silas, "Sotatercept Effectively Treats Anemia in MDS and Non-Proliferative CMML", onclive.com, onclive.com, URL: https://www.onclive.com/view/sotatercept-effectively-treats-anemia-in-mds-and-non-proliferative-cmml, XP093266234 | - |
| OPPOSITION | - M.D. Anderson Cancer Center, "Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia - NCT01712308", Clinical Trials, ClinicalTrials.gov, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT01712308?term=nct01712308&rank=1&tab=history&a=19#version-content-panel, XP093266248 | - |
| OPPOSITION | - Platzbecker Uwe, A Giagounidis, U Germing, K Götze, P Kiewe, K Mayer, J Chromik, M Radsak, T Wolff, E Donovan, D Wilson, X Zhang, A Laadem, M Sherman, K Attie, "LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW-INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MOS STUDY", Abstract S131, page 16, Conference abstract, 21th Congress of the European Hematology Association; Presented at the conference on June 9 - 12, 2016, (20160609), page S16, XP093266181 | - |
| OPPOSITION | - Starr Phoebe, "The Hematologic Drug Pipeline: Exciting New Treatment Options Looming", American Health & Drug Benefits, (20160201), vol. 9, XP093266168 | - |
| OPPOSITION | - University Of Ulm, "Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary MF (POMINC) - NCT01644110", GenSeq Nucleic Acids, Clinical Trials, clinicaltrials.gov, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT01644110?tab=history&a=3#ve rsion-content-panel , XP093276482 | - |
| OPPOSITION | - U. Platzbecker, U. Germing, A. Giagounidis, K. Götze, P. Kiewe, K. Mayer, O. Ottmann, M. Radsak, T. Wolff, D. Haase, M. Hankin, D. Wilson, X. Zhang, A. Laadem, M. Sherman, K. Attie, "Abstract S509 LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM THE PHASE 2 PACE-MDS STUDY", Haematologica, (20150601), vol. 100, no. Suppl. 1, ISSN 0390-6078, page 192, XP009558263 | - |
| OPPOSITION | - Kenneth M. Attie, Mark J. Allison, Ty Mcclure, Ingrid E. Boyd, Dawn M. Wilson, Amelia E. Pearsall, Matthew L. Sherman, "A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers", AMERICAN JOURNAL OF HEMATOLOGY, NEW YORK, NY, US, US , (20140701), vol. 89, no. 7, doi:10.1002/ajh.23732, ISSN 0361-8609, pages 766 - 770, XP055321131 | |
| OPPOSITION | - Naseema Gangat; Mrinal M. Patnaik; Ayalew Tefferi, "Myelodysplastic syndromes: Contemporary review and how we treat", AMERICAN JOURNAL OF HEMATOLOGY, NEW YORK, NY, US, US , (20151223), vol. 91, no. 1, doi:10.1002/ajh.24253, ISSN 0361-8609, pages 76 - 89, XP071630722 | |
| OPPOSITION | - Quintás-Cardama A; Tong W; Kantarjian H; Thomas D; Ravandi F; Kornblau S; Manshouri T; Cortes J E; Garcia-Manero G; Verstovsek S, "A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20080403), vol. 22, no. 5, doi:10.1038/leu.2008.91, ISSN 0887-6924, pages 965 - 970, XP037785926 | |
| OPPOSITION | - A Pardanani, A M Vannucchi, F Passamonti, F Cervantes, T Barbui, A Tefferi, "JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations", Leukemia, Stockton Press, (20110201), vol. 25, no. 2, doi:10.1038/leu.2010.269, ISSN 08876924, pages 218 - 225, XP055116971 | |
| OPPOSITION | - E Bulycheva, M Rauner, H Medyouf, I Theurl, M Bornhäuser, L C Hofbauer, U Platzbecker, "Myelodysplasia is in the niche: novel concepts and emerging therapies", Blood Cancer Journal, Nature Publishing Group UK, London, London, (20150201), vol. 29, no. 2, doi:10.1038/leu.2014.325, ISSN 0887-6924, pages 259 - 268, XP055518203 | |
| OPPOSITION | - Michael Dussiot, Et Al, "An activin receptor IIA ligand trap corrects ineffective erythropoiesis in &bgr;-thalassemia", Nature Medicine(Author manuscript ), Nature Publishing Group US, New York, New York, vol. 20, no. 4, doi:10.1038/nm.3468, ISSN 1078-8956, pages 398 - 407, XP055423095 | |
| OPPOSITION | - Rajasekhar N V S Suragani, Samuel M Cadena, Sharon M Cawley, Dianne Sako, Dianne Mitchell, Robert Li, Monique V Davies, Mark J Alexander, Matthew Devine, Kenneth S Loveday, Kathryn W Underwood, Asya V Grinberg, John D Quisel, Rajesh Chopra, R Scott Pearsall, Jasbir Seehra, Ravindra Kumar, "Transforming growth factor-&bgr; superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis", Nature Medicine(Author manuscript ), Nature Publishing Group US, New York, New York, vol. 20, no. 4, doi:10.1038/nm.3512, ISSN 1078-8956, pages 408 - 414, XP055410209 | |
| OPPOSITION | - Komrokji R.S., List A.F., "Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes", Annals of Oncology, Elsevier, (20160101), vol. 27, no. 1, doi:10.1093/annonc/mdv488, ISSN 0923-7534, pages 62 - 68, XP093266190 | |
| OPPOSITION | - Francisco Cervantes; Alberto Alvarez‐Larrán; Juan‐Carlos Hernández‐Boluda; Ana Sureda; Montserrat Torrebadell; Emili Montserrat, "Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature", British Journal of Haematology, John Wiley, Hoboken, USA, Hoboken, USA, (20041021), vol. 127, no. 4, doi:10.1111/j.1365-2141.2004.05229.x, ISSN 0007-1048, pages 399 - 403, XP071053941 | |
| OPPOSITION | - Tsiara SN, Chaidos A, Bourantas LK, Kapsali HD, Bourantas KL., "Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis", ACTA HAEMATOLOGICA, S. KARGER, BASEL, CH, CH , (20070301), vol. 117, no. 3, doi:10.1159/000097463, ISSN 0001-5792, pages 156 - 161, XP009560420 | |
| OPPOSITION | - Tefferi Ayalew, "How I treat myelofibrosis", Blood, (20110331), vol. 117, no. 13, doi:10.1182/blood-2010-11-315614, pages 3494 - 3504, XP093266206 | |
| OPPOSITION | - Jabbour Elias, Thomas Deborah, Kantarjian Hagop, Zhou Lingsha, Pierce Sherry, Cortes Jorge, Verstovsek Srdan, "Comparison of thalidomide and lenalidomide as therapy for myelofibrosis", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20110728), vol. 118, no. 4, doi:10.1182/blood-2010-12-325589, ISSN 0006-4971, pages 899 - 902, XP093266193 | |
| OPPOSITION | - Tefferi Ayalew, Cervantes Francisco, Mesa Ruben, Passamonti Francesco, Verstovsek Srdan, Vannucchi Alessandro M., Gotlib Jason, Dupriez Brigitte, Pardanani Animesh, Harrison Claire, Hoffman Ronald, Gisslinger Heinz, Kröger Nicolaus, Thiele Juergen, Barbui Tiziano, Barosi Giovanni, "Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20130822), vol. 122, no. 8, doi:10.1182/blood-2013-03-488098, ISSN 0006-4971, pages 1395 - 1398, XP093276415 | |
| OPPOSITION | - R. N. V. S. Suragani, Cawley S. M., Li R., Wallner S., Alexander M. J., Mulivor A. W., Gardenghi S., Rivella S., Grinberg A. V., Pearsall R. S., Kumar R., "Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine -thalassemia", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20140619), vol. 123, no. 25, doi:10.1182/blood-2013-06-511238, ISSN 0006-4971, pages 3864 - 3872, XP055423087 | |
| OPPOSITION | - Bose Prithviraj; Verstovsek Srdan, "JAK2 inhibitors for myeloproliferative neoplasms: what is next?", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20170713), vol. 130, no. 2, doi:10.1182/blood-2017-04-742288, ISSN 0006-4971, pages 115 - 125, XP086677028 | |
| OPPOSITION | - Gerds Aaron T., Harrison Claire, Kiladjian Jean-Jacques, Mesa Ruben, Vannucchi Alessandro M., Komrokji Rami, Bose Prithviraj, Kremyanskaya Marina, Mead Adam J., Gotlib Jason, Rose Shelonitda, Sanabria Fabian, Marsousi Niloufar, Giuseppi Ana Carolina, Jiang Huijing, Palmer Jeanne M., Mccaul Kelly, Ribrag Vincent, Passamonti Francesco, "Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis", Blood Advances, American Society of Hematology, (20240910), vol. 8, no. 17, doi:10.1182/bloodadvances.2024012939, ISSN 2473-9529, pages 4511 - 4522, XP093266183 | |
| OPPOSITION | - Suragani Rajasekhar NVS; Martinez Pedro A.; Cawley Sharon M; Li Robert; Pearsall Robert Scott; Kumar Ravindra, "TGFb1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20151203), vol. 126, no. 23, doi:10.1182/blood.V126.23.605.605, ISSN 0006-4971, page 605, XP086649454 | |
| OPPOSITION | - Stegelmann Frank; Bangerter Markus; Heidel Florian H; Griesshammer Martin; Hebart Holger; Hochhaus Andreas; Koschmieder Steffen; Möhle Robert; Reiter Andreas; Scheid Christof; Kirschbaum Rebecca; Reim Regina; Sutter Ulrike; Vetter Katrin; Döhner Hartmut; Schlenk Richard F.; Döhner Konstanze, "A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20151203), vol. 126, no. 23, doi:10.1182/blood.V126.23.826.826, ISSN 0006-4971, page 826, XP086644884 | |
| OPPOSITION | - Giagounidis Aristoteles; Platzbecker Uwe; Germing Ulrich; Götze Katharina; Kiewe Philipp; Mayer Karin Tina; Ottmann Oliver; Radsak Markus; Wolff Thomas; Haase Detlef; Hankin Monty; Wilson Dawn; Zhang Xiaosha; Laadem Adberrahmane; Sherman Matthew L.; Attie Kenneth M., "Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20151203), vol. 126, no. 23, doi:10.1182/blood.V126.23.92.92, ISSN 0006-4971, page 92, XP086639634 | |
| OPPOSITION | - Stegelmann Frank, Hebart Holger, Bangerter Markus, Wolleschak Denise, Griesshammer Martin, Koschmieder Steffen, Von Bubnoff Nikolas, Möhle Robert, Kindler Thomas, Hochhaus Andreas, Heidel Florian H., Reiter Andreas, Scheid Christof, Kirschbaum Rebecca, Reim Regina, Sutter Ulrike, Vetter Katrin, Döhner Hartmut, Schlenk Richard F., Döhner Konstanze, "Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110)", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20161202), vol. 128, no. 22, doi:10.1182/blood.V128.22.1939.1939, ISSN 0006-4971, pages 1939 - 1939, XP093276478 | |
| OPPOSITION | - Bose Prithviraj, Daver Naval, Jabbour Elias J., Pike Allison, Newberry Kate J, Zhou Lingsha, Pierce Sherry, Wang Xuemei, Kantarjian Hagop M., Verstovsek Srdan, "Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20161202), vol. 128, no. 22, doi:10.1182/blood.V128.22.478.478, ISSN 0006-4971, pages 478 - 478, XP093276491 | |
| OPPOSITION | - Stein Richard S., Abels Robert I., Krantz Sanford B., "Pharmacologic Doses of Recombinant Human Erythropoietin in the Treatment of Myelodysplastic Syndromes", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19911001), vol. 78, no. 7, doi:10.1182/blood.V78.7.1658.1658, ISSN 0006-4971, pages 1658 - 1663, XP093266185 | |
| OPPOSITION | - Mcmullin Mary Frances, Harrison Claire N., Niederwieser Dietger, Demuynck Hilde, Jäkel Nadja, Gopalakrishna Prashanth, Mcquitty Mari, Stalbovskaya Viktoriya, Recher Christian, Theunissen Koen, Gisslinger Heinz, Kiladjian Jean-Jacques, Al-Ali Haifa-Kathrin, "The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis", Experimental Hematology & Oncology, BioMed Central Ltd, London, UK, London, UK , (20151201), vol. 4, no. 1, doi:10.1186/s40164-015-0021-2, ISSN 2162-3619, XP093276487 | |
| OPPOSITION | - TEFFERI AYALEW, ET AL, "Pomalidomide is active in the treatment of anemia associated with myelofibrosis", Journal of Clinical Oncology, (20090920), vol. 27, no. 27, doi:10.1200/JCO.2008.21.7356, pages 4563 - 4569, XP002669498 | |
| OPPOSITION | - Emanuel Robyn M., Dueck Amylou C., Geyer Holly L., Kiladjian Jean-Jacques, Slot Stefanie, Zweegman Sonja, Te Boekhorst Peter A.W., Commandeur Suzan, Schouten Harry C., Sackmann Federico, Kerguelen Fuentes Ana, Hernández-Maraver Dolores, Pahl Heike L., Griesshammer Martin, Stegelmann Frank, Doehner Konstanze, Lehmann Thomas, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Harrison Claire N., Radia Deepti, Muxi Pablo, Maldonado Norman, Besses Carlos, Cervantes Francisco, Johansson Peter L., Barbui Tiziano, Barosi Giovanni, Vannucchi Alessandro M., Passamonti Francesco, Andreasson Bjorn, Ferarri Maria L., Rambaldi Alessandro, Samuelsson Jan, Birgegard Gunnar, Tefferi Ayalew, Mesa Ruben A., "Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs", Journal of Clinical Oncology, American Society of Clinical Oncology, (20121120), vol. 30, no. 33, doi:10.1200/JCO.2012.42.3863, ISSN 0732-183X, pages 4098 - 4103, XP093276409 | |
| OPPOSITION | - K. Haddley, "Luspatercept. TGF-beta inhibitor, Antianemic, Hematopoietic agent", Drugs of the Future, Prous Science, ES, ES , (20150101), vol. 40, no. 5, doi:10.1358/dof.2015.040.05.2336972, ISSN 0377-8282, pages 293 - 299, XP009560419 | |
| OPPOSITION | - Marisavljević Dragomir, Rolović Z, Cemerikić V, Bosković D, Colović M, "Myelofibrosis in Primary Myelodysplastic Syndromes", Medical Oncology, (20040101), vol. 21, no. 4, doi:10.1385/MO:21:4:325, pages 325 - 331, XP093266211 | |
| OPPOSITION | - Vaddi Kris, Sarlis Nicholas J, Gupta Vikas, "Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis", Expert Opin Pharmacother, Ashley Publications LTD, London, UK, London, UK , (20121101), vol. 13, no. 16, doi:10.1517/14656566.2012.732998, ISSN 1465-6566, pages 2397 - 2407, XP093266214 | |
| OPPOSITION | - Rosenthal Allison, Mesa Ruben A, "Janus kinase inhibitors for the treatment of myeloproliferative neoplasms", Expert Opin Pharmacother, Ashley Publications LTD, London, UK, London, UK , (20140601), vol. 15, no. 9, doi:10.1517/14656566.2014.913024, ISSN 1465-6566, pages 1265 - 1276, XP093266203 | |
| OPPOSITION | - Kaminskas Edvardas, Farrell Ann T., Wang Yong‐cheng, Sridhara Rajeshwari, Pazdur Richard, "FDA Drug Approval Summary: Azacitidine (5‐azacytidine, Vidaza™) for Injectable Suspension", THE ONCOLOGIST, AlphaMed Press, (20050301), vol. 10, no. 3, doi:10.1634/theoncologist.10-3-176, ISSN 1083-7159, pages 176 - 182, XP093266198 | |
| OPPOSITION | - Pardanani A., Tefferi A., "Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis", Haematologica, (20110101), vol. 96, no. 1, doi:10.3324/haematol.2010.035519, ISSN 0390-6078, pages 8 - 10, XP093266212 | |
| OPPOSITION | - Mughal T. I., Cross N. C. P., Padron E., Tiu R. V., Savona M., Malcovati L., Tibes R., Komrokji R. S., Kiladjian J.-J., Garcia-Manero G., Orazi A., Mesa R., Maciejewski J. P., Fenaux P., Itzykson R., Mufti G., Solary E., List A. F., "An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms", Haematologica, (20150901), vol. 100, no. 9, doi:10.3324/haematol.2014.114660, ISSN 0390-6078, pages 1117 - 1130, XP093266208 | |
| SEARCH | - Anonymous, "A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence. | Journal of Clinical Oncology", (20180101), URL: https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.TPS7083, (20201014), XP055739720 [IP] 1-15 * the whole document * | - |
| SEARCH | - Anonymous, "History of Changes for Study: NCT03194542", (20170620), URL: https://clinicaltrials.gov/ct2/history/NCT03194542?V_1=View#StudyPageTop, (20201014), XP055739721 | - |
| SEARCH | - RAJASEKHAR N V S SURAGANI ET AL, "Transforming growth factor-&bgr; superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis", NATURE MEDICINE, New York, (20140323), vol. 20, no. 4, doi:10.1038/nm.3512, ISSN 1078-8956, pages 408 - 414, XP055410209 [Y] 1-15 * the whole document * | |
| SEARCH | - R. N. V. S. SURAGANI ET AL, "Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine ?-thalassemia", BLOOD, US, (20140502), vol. 123, no. 25, doi:10.1182/blood-2013-06-511238, ISSN 0006-4971, pages 3864 - 3872, XP055423087 [Y] 1-15 * the whole document * | |
| SEARCH | - Archana Agarwal ET AL, "Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-[beta]", Stem cell investigation, China, doi:10.3978/j.issn.2306-9759.2016.02.03, (20160101), pages 5 - 5, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923632/pdf/sci-03-2016.02.03.pdf, XP055738249 [I] 1-15 * the whole document * | |
| SEARCH | - KEOHANE C ET AL, "Ruxolitinib for myelofibrosis", CLINICAL INVESTIGATION, FUTURE SCIENCE, UK, (20120930), vol. 2, no. 10, doi:10.4155/CLI.12.94, ISSN 2041-6792, pages 1023 - 1031, XP009519059 [Y] 1-15 * the whole document * | |
